NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with PDS Biotechnology Corporation.
Toni had the pleasure of recently conducting the Interview with Dr. Frank Bedu-Addo, CEO PDS Biotechnology Corporation (NASDAQ:PDSB). Toni diligently focused on questions she thought would be on the minds of most current and potential future shareholders. See interview highlights below.
Access this interview in its entirety at https://tradersnewssource.com/interview-pdsb/
FRANK BEDU-ADDO, PH.D
Chief Executive Officer, Director
Dr. Bedu-Addo has served as a director president and CEO of PDS Biotech since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health's East Coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.
Interview Highlights:
Traders News Source Editor Toni Loudenbeck and Frank Bedu-Addo, PH.D discuss an overview of the company, the product pipeline, potential timeframes on new revenue streams, PDS's proprietary platform plus much more in this interview.
Access this interview in its entirety at https://tradersnewssource.com/interview-pdsb/.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimune based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
About Traders News Source (TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit: https://tradersnewssource.com/interview-pdsb/
Media Contact
Traders News Source
Mark Roberts, Senior Editor
Editor@TradersNewsSource.com
SOURCE: Traders News Source LLC
View source version on accesswire.com:https://www.accesswire.com/730010/In-a-New-Audio-Interview-Toni-Loudenbeck-of-Traders-News-Source-Interviews-Dr-Frank-Bedu-Addo-CEO-PDS-Biotechnology-Corporation
